Marksans Pharma share news, announcements and annual reports
NSE: MARKSANSBSE: 524404Pharmaceuticals & BiotechnologySmall Cap
Marksans Pharma Limited · Formerly Tasc Pharmaceuticals · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1994 on BSE, Jan 2002 on NSE
Last close ₹306.20down ₹9.15 (2.90%)BSE ₹306.65
Share price at the NSE close on 30 Oct 2026. Previous close ₹315.35.
30 Oct: open ₹317.00, high ₹317.35, low ₹304.90
52-week range of traded prices to 30 Oct 2026
₹155.00Low, 30 Mar 2026₹350.95High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹13,876 Cr592nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.85
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.59
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.29%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 17.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 19.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 12,10,63344.3% delivered
Marksans Pharma orders, deals and press releases
130 filed, newest first. Page 3 of 3.
Feb 2018
12 Feb · Business
Nov 2017
Oct 2017
Aug 2017
11 Aug · Business
May 2017
29 May · Business
10 May · Business
Apr 2017
Feb 2017
Nov 2016
Oct 2016
Sep 2016
Aug 2016
May 2016
30 May · Business
Feb 2016
Nov 2015
10 Nov · Business
Aug 2015
Jun 2015
May 2015
Mar 2015
Feb 2015
Oct 2014
Aug 2014
May 2014
Jul 2009
21 Jul · Business
Press release dated July 21, 2009, titled "Marksans Pharma Limited announces USFDA approval of generic Ibuprofen Capsules (Liquid Filled), 200 mg for Advil Liqui-Gels 200mg". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2008
28 Aug · Business
"Marksans Pharma Limited's subsidiary, Marksans Pharma (UK) Limited, has entered into a definitive agreement to acquire 100% of the share capital of RelonCehm Limited." The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2008
7 Jan · Business
"Marksans Pharma Limited's subsidiary, Marksans Pharma (UK) Limited, has entered into a definitive agreement to acquire 100% of the share capital of Hale Group Limited, the parent company of Bell, Sons & Co (Druggists) Limited ("Bell"). Through this acquisition, Marksans will have access to 34 product licenses of Bell, situated near Liverpool, in the UK". The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Dec 2007
31 Dec · Business
At the Board meeting of the Company held on 31st December, 2007 following decisions were taken: 1) Consent of the Board of Directors of the Company for entering into Share Purchase Agreement with Hale Group Limited, U.K. for acquiring its entire share capital along with its subsidiary Company Bell, Sons & Co. (Druggists) Limited and authority to Mr. Mark Saldanha, Managing Director to execute the same. The above acquisition shall be through Companies 100% subsidiary, Marksans Pharma U.K. Limited; 2) Shifting the Registered office of the Company from 601-622, Chintamani Plaza, Mohan Studio Compound, Andheri- Kurla Road, Andheri (E), Mumbai 400 099 to 21st Floor, Lotus Business Park, Off New Link Road, Andheri (W), Mumbai 400 053
Feb 2007
15 Feb · Business
Hon. High Court, Mumbai, has ordered Amalgamation of Mark Remedies Limited (a 100 % Subsidiary of Marksans Pharma Limited) with Marksans Pharma Limited